hepatitis C

Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C
CP Wire
Gilead Sciences
generics
Epclusa
Harvoni
hepatitis C
Asegua Therapeutics
Flag link:
Inovio launches Ph1 study of Hep C vaccine
Inovio launches Ph1 study of Hep C vaccine
Drug Delivery Business News
Inovio
vaccines
GeneOne Life Science
hepatitis C
GLS-6150
Flag link:
Louisiana seeking comments on 'Netflix' model for hepatitis C drugs
Louisiana seeking comments on 'Netflix' model for hepatitis C drugs
Fierce Pharma
hepatitis C
Medicaid
Louisiana
Flag link:
2019 Express Scripts Formulary Exclusions: Hepatitis C Changes Show Why the Drug Channel Must Change, Too
2019 Express Scripts Formulary Exclusions: Hepatitis C Changes Show Why the Drug Channel Must Change, Too
Drug Channels
Express Scripts
CVS Health
formulary
drug channels
hepatitis C
Flag link:
Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry
Gilead loses key patent claims for Sovaldi in China, opening door to earlier generic entry
Endpoints
China
Gilead Sciences
hepatitis C
generics
Sovaldi
Flag link:
Merck’s 60% price cut for hepatitis C drug nets company a big sales opportunity
Merck’s 60% price cut for hepatitis C drug nets company a big sales opportunity
Marketwatch
Merck
Express Scripts
hepatitis C
Zepatier
Flag link:
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019
Bloomberg
Express Scripts
PBMs
Gilead Sciences
HIV
Atripla
AbbVie
Mavyret
hepatitis C
Flag link:
AbbVie surprised investors with its hepatitis C success. Will it last?
AbbVie surprised investors with its hepatitis C success. Will it last?
Biopharma Dive
AbbVie
hepatitis C
Mavyret
Flag link:
Merck touts a 60% price cut, but the drug is outdated and on the way out
Merck touts a 60% price cut, but the drug is outdated and on the way out
Marketwatch
Merck
Zepatier
hepatitis C
drug pricing
Flag link:
Merck lowers prices of some drugs after Trump calls out industry
Merck lowers prices of some drugs after Trump calls out industry
Yahoo/Reuters
Merck
drug pricing
Donald Trump
hepatitis C
Flag link:
Private Insurers Deny Over Half of All Claims for Hepatitis C Drugs
Private Insurers Deny Over Half of All Claims for Hepatitis C Drugs
Xtalks
hepatitis C
insurers
Flag link:
Balm for Gilead: Unclean Hands Render Patents Unenforceable
Balm for Gilead: Unclean Hands Render Patents Unenforceable
JD Supra
Merck
Gilead Sciences
patents
hepatitis C
Flag link:
The hepatitis C duopoly
The hepatitis C duopoly
Axios
AbbVie
hepatitis C
Gilead Sciences
Flag link:
U.S. court upholds dismissal of $200 million Merck verdict against Gilead
U.S. court upholds dismissal of $200 million Merck verdict against Gilead
Reuters
Merck
Gilead Sciences
patents
hepatitis C
Flag link:
This Small Biotech Is Building on a Surprising Success
This Small Biotech Is Building on a Surprising Success
Motley Fool
AbbVie
Mavyret
Enanta Pharmaceuticals
glecaprevir
hepatitis C
Flag link:
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Xconomy
Conatus Pharmaceuticals
clinical trials
Novartis
emricasan
liver disease
hepatitis C
Flag link:
5 Must-See Quotes From AbbVie's Management
5 Must-See Quotes From AbbVie's Management
Yahoo/Motley Fool
AbbVie
Humira
hepatitis C
Mavyret
Viekira
M&A
Flag link:
Is Gilead Sciences Trying to Put Itself Out of Business?
Is Gilead Sciences Trying to Put Itself Out of Business?
Motley Fool
Gilead Sciences
hepatitis C
HIV
GS-9620
PGT121
Flag link:
[video]How Pricing Can Be Vital to a Drugmaker's Profitability
[video]How Pricing Can Be Vital to a Drugmaker's Profitability
Motley Fool
drug pricing
Gilead Sciences
AbbVie
hepatitis C
Flag link:
Gilead Sciences' History Points to Future Success
Gilead Sciences' History Points to Future Success
Motley Fool
Gilead Sciences
hepatitis C
NASH
Flag link:

Pages